Correlation of Glucose and Lipid Metabolism Levels With Vitiligo

Sponsor
Xijing Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05968235
Collaborator
(none)
963
1
37.7
25.5

Study Details

Study Description

Brief Summary

The goal of this observational study is to compare serum glucose and lipid metabolism levels between health volunteers and vitiligo patients. The main question it aims to answer is whether vitiligo is related to glucose and lipid metabolism disorders. Participants will complete a vitiligo questionnaire and test serum levels of indicators related to glucose and lipid metabolism. Researchers will compare vitiligo patients with healthy volunteers to see if there is a correlation between vitiligo and disorders of glucose and lipid metabolism.

Condition or Disease Intervention/Treatment Phase
  • Other: Collecting blood samples

Detailed Description

Vitiligo is a common autoimmune skin disease, which causes white spot formation due to destruction of epidermal melanocytes, severely affecting the physical and mental health of patients, but treatment is extremely difficult due to unclear pathogenesis. Studies have reported that patients with type I diabetes mellitus combined with vitiligo, the risk of metabolic syndrome, diabetes mellitus, elevated lipids, and obesity in vitiligo patients is higher than that of healthy controls, and other studies have reported that vitiligo lesions in patients with hypercholesterolemia combined with vitiligo treated with simvastatin get rapid skin color, suggesting that there is a correlation between glucose and lipid metabolism and the vitiligo disease, but as of now there is no research study on the correlation of glucose and lipid metabolism and vitiligo pathogenesis, much less large data can be analyzed for reference. Therefore, there is an urgent need to study the metabolic profile of vitiligo patients and utilize the basic research platform to explore the role of abnormal body metabolism in the onset or progression of vitiligo.

This study intends to conduct a cross-sectional study, using questionnaires to collect and register vitiligo patients' disease information, etc., to establish a database of study subjects, and to collect peripheral blood samples from vitiligo patients to test the levels of key indicators of glycolipid and lipid metabolism, and to analyze their correlation with clinical features, disease activity, and treatment of vitiligo. Through the above studies, clinical evidence for the involvement of abnormalities in glycolipid and lipid metabolism in the development of vitiligo was provided.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
963 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Association of Glucose and Lipid Metabolism Levels and Vitiligo : a Case-control Study
Actual Study Start Date :
Feb 1, 2020
Actual Primary Completion Date :
Mar 25, 2022
Actual Study Completion Date :
Mar 25, 2023

Arms and Interventions

Arm Intervention/Treatment
Vitiligo

Patients diagnosed with vitiligo

Other: Collecting blood samples
Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.

Healthy

Healthy volunteers with sex- and age-matched with vitiligo patients

Other: Collecting blood samples
Peripheral blood was collected from the study subjects and blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoprotein and low-density lipoprotein levels were measured in the peripheral blood.

Outcome Measures

Primary Outcome Measures

  1. Demographic and epidemiological information of the study subjects [2020.02.01-2023.03.25]

    Detailed records of demographic information (age, gender, occupation, education degree, life history, et al.), clinical information of vitiligo (age at onset, duration, severity, type, treatment, complication, et al.) and physical examination index (height, weight, blood pressure, heart rate).

  2. Serum glucose and lipid metabolism levels of the study subjects [2020.02.01-2023.03.25]

    Detection of fasting blood glucose, glycosylated hemoglobin, triglycerides, total cholesterol, high-density lipoproteins, and low-density lipoproteins in peripheral blood of study subjects.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Patients diagnosed as vitiligo by a dermatologist based on a combination of clinical manifestations (milky white or porcelain white patches), Wood's Lamp test results (bright white fluorescence), and histopathologic test results (reduction or disappearance of epidermal melanocytes in the white patches);

  2. Male or female subjects, age between 18 and 60 years old;

  3. Stable vital signs;

  4. Study subjects voluntarily signed an informed consent form.

Exclusion Criteria:
  1. Subjects who have been systematically using glucocorticoids, immunosuppressants, etc. that affect glycolipid levels due to a combination of diseases other than metabolic diseases in the last 3 months shall be asked and determined by a clinician;

  2. Women who are pregnant or breastfeeding shall be asked and determined by a clinician;

  3. Subjects who suffer from psychiatric disorders, etc. and who are not capable of cooperating with the follow-up study shall be asked and determined by a clinician.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xijing Hospital Xi'an Shaanxi China 710032

Sponsors and Collaborators

  • Xijing Hospital

Investigators

  • Principal Investigator: Chunying Li, Air Force Military Medical University, China

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Li Chunying-1, Vice Chief, Xijing Hospital
ClinicalTrials.gov Identifier:
NCT05968235
Other Study ID Numbers:
  • XJPF-LCY-V202307
First Posted:
Aug 1, 2023
Last Update Posted:
Aug 1, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Li Chunying-1, Vice Chief, Xijing Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2023